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E-mail address: campisi@odonto.unipa.it (G. CampBackground: HR HPV infection was proposed as aetiological factor of oral squamous cell carcinomas
(OSCC). HPV frequency in OSCC is highly variable, due to the discrepancy in oral sampling procedures,
HPV testing methods and inclusion criteria regarding tumour site (strictly oral cavity vs. nearby struc-
tures). Our aim was to compare HPV DNA frequency and type-speciﬁc distribution in paired cytological
and histological samples of SCC strictly located in oral cavity. The correlation between HPV detection rate
by each method of sampling and demographical, behavioural and clinical–pathological variables was also
examined.
Patients and methods: HPV DNA was detected in brushed cells and formalin-ﬁxed parafﬁn-embedded
biopsies obtained from 83 consecutive unselected immunocompetent adults with OSCC. HPV DNA detec-
tion was performed in all samples by nPCR followed by direct DNA sequencing and the assay INNO-LiPA
HPV Genotyping. Univariate and multivariate statistics were used, including Cohen j index to evaluate
agreement between two methods and association between HPV infection and demographical, behav-
ioural and clinical–pathological variables for each method of sampling (p < 0.05 statistically signiﬁcant).
Results: HPV DNA was detected in 15.7% (13/83) of brushings and 12.1% (10/83) of biopsies (p > 0.05).
High risk HPV 51, 16 and 39 were genotypes more frequently detected, especially among biopsies; no
concordance between two methods was found (Cohen j index = 0.04, p = 0.34).
Conclusion: A fraction of OSCC could be linked to HR HPV infection in the Mediterranean area. Although
without a statistical signiﬁcance, biopsy specimen demonstrated more accurate for HR HPV detection
than brushing in OSCC.
 2012 Elsevier Ltd. All rights reserved.Introduction
In 1995 the International Agency for Research on Cancer de-
ﬁned the High Risk (HR) Human Papilloma Virus (HPV) types 16
and 18 as carcinogenic agents in humans,1 which are responsible
for the development of approximately 90% cases of squamous cell
carcinoma of the uterine cervix.2–7 HR HPVs have also been pro-
posed as aetiological factors of various head and neck squamous
cell carcinomas (HNSCC),8 tonsillar and oral squamous cell carci-
noma (OSCC). Strictly deﬁned, OSCC (i.e. that arising from the area
of the mucosa – anterior palatal pillars) accounts for the majority
of HNSCC cases. According to recent epidemiological data, the
worldwide incidence of OSCC in the general population is aboutll rights reserved.
urgical and Oncologic Disci-
7 Palermo, Italy. Tel./fax: +39
isi).3.8% and this percentage is higher in more developed countries,
including southern Europe (7.5% for males and 2.4% for females),
than in less developed countries (4.6% for males and 2.6% for
females) (source: GLOBOCAN http://www.globocan.iarc.fr/
factsheets/populations/factsheet.asp?uno=900#BOTH). According
to the latest report of the Italian Association of Cancer Registries
(AIRTUM, http://www.registri-tumori.it/cms_en/), the incidence
of OSCC in southern Italy is moderately high (about 11/100,000
cases per year). Although smoking tobacco and alcohol abuse are
the main risk factors, a fraction of patients with OSCC are
non-smokers and non-drinker subjects,9 and an HPV-induced car-
cinogenesis has been proposed10,11; this particularly regards young
patients and those with behavioural risk factors (a history of a high
number of sexual partners and practising oral sex).12,13
It has been reported in recent years that a signiﬁcant share
(about 60%) of oropharyngeal cancers (base of the tongue and
tonsillar SCC) harbour HPV DNA and thus they could be
HPV-related.14–17 However, the role of HPV in the carcinogenesis
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pic16,18,19 due to the widest range of viral prevalence (0–100%)
hereto reported, together with the identiﬁcation of HR HPV in nor-
mal oral mucosa.20–24 Apart from the ethno-geographical and so-
cio-behavioural differences among the populations studied, this
wide range of prevalence could be related to the inaccurate classi-
ﬁcation as oral cavity SCC, with respect to oropharyngeal SCC, and
to the sensitivity of the diagnostic methods involved. This supposi-
tion brings to mind the low viral productivity of oral infection25
and the need for a highly sensitive and speciﬁc method of HPV
detection. Several procedures regarding the collection of oral spec-
imens have been evaluated in the literature,2,26,27 in the absence of
an accepted standard sampling method for OSCC patients. Two
types of oral samples are generally available: tissue specimens (ob-
tained by biopsy) and exfoliated epithelial cells (collected by the
direct scraping/brushing of oral mucosa or by oral rinse).
The aims of this investigation were: (i) to compare the fre-
quency and the type-speciﬁc distribution of HPV genotypes in
paired cytological (brushings) and histological samples (parafﬁn-
embedded biopsies) in patients with SCC, located strictly in the
oral cavity and detected by a highly sensitive HPV test; and (ii)
to investigate the association between the HPV detection rate by
each method of sampling and the main demographical, behav-
ioural and clinical–pathological variables.Patients and methods
This hospital-based study included 83 consecutive immuno-
competent adults with SCC located strictly in the oral cavity, re-
cruited from the Unit of Oral Medicine (University of Palermo)
over a 4-year period (January 2007–December 2010). Subjects with
oropharyngeal SCC (arising from mucosa behind the anterior pala-
tal pillars) were excluded, according to AJCC criteria.28 Each patient
was initially subjected to biopsy and histopathological examina-
tions, in conﬁrming a diagnosis of OSCC, and then to cytological
sampling by brushing, as described below:
(i) Biopsy: After local anaesthesia, an incision was performed
with a traditional scalpel. Specimens were obtained from
each patient from a non-necrotic area of the tumour prior
to any treatment for cancer. Ten micrometre tissue sections
of formalin-ﬁxed parafﬁn-embedded biopsies from con-
ﬁrmed OSCC patients were obtained. Sterile microtome
blades were used for sectioning each specimen to reduce
contamination.
(ii) Brushing: Samples of oral mucosal cells were obtained by
brushing (Cytobrush: RAM, Mirandola, Modena, Italy) from
the site of the lesion; ﬁve complete backward and forward
brushes were performed at each site. The brush was imme-
diately squeezed onto the side of a tube containing 5 mL of
cold phosphate-buffered saline.
Demographical and behavioural information (gender, age,
smoking habit and alcohol use) and clinical-pathological data (sites
and histological grading) were recorded. Informed consent was ob-
tained from all patients, with submission of the study to the local
EC. Subjects were grouped into two smoking categories [smoker (at
least ﬁve cigarettes/day) and non-smoker] and two alcohol con-
sumption categories [drinker (at least 200 mL/day of alcoholic bev-
erages) and non-drinker (no alcohol or less than 200 mL/day)].
Each mucosal site of the oral cavity was separately considered
and also grouped as keratinized (masticatory mucosa of hard pal-
ate and gingiva, specialised mucosa of the dorsal surface of tongue)
vs. non-keratinized (labial, alveolar and cheek mucosa, soft palate,
mouth ﬂoor and ventral and lateral surface of the tongue).DNA extraction and HPV DNA detection
(i) Biopsy: To isolate DNA, two formalin-ﬁxed, parafﬁn-embed-
ded sections were incubated overnight at 56 C in 250 lL of
a 0.5% Tween 20, 50 mM Tris–HCl pH 8.5, 1 mM EDTA, con-
taining 300 lg mL-1 of proteinase K solution. Proteinase K
was inactivated at 95 C for 10 min. The samples were cen-
trifuged for 5 min at 13,000 rpm, and total DNA was
extracted with a High Pure PCR Template Preparation kit
(Roche Diagnostics GmbH, Mannheim, Germany), following
the manufacturer’s instructions.
(ii) Brushing: After collection, oral specimens were centrifuged
at 2,000 rpm for 10 min, washed with saline solution, centri-
fuged at 12,000 rpm for 10 min, and the pellet stored at
20 C. Total DNA was extracted by means of a High Pure
PCR Template Preparation kit (Roche Diagnostics GmbH,
Mannheim, Germany), following the manufacturer’s
instructions.
All samples were checked for DNA quality by the standard
ampliﬁcation of human b-globin, as described elsewhere29; only
b-globin-positive samples were examined for HPV DNA. Samples
were tested in duplicate; controls of ampliﬁcations were blank
controls, the HPV DNA negative human Wi-38 cell line was used
as a negative control and the HPV DNA positive human cell line
SiHa (1–2 copies of HPV-16 DNA per cell) was used as a positive
control. SiHa dilutions from 104 (10,000–20,000 HPV-16 DNA cop-
ies) down to 10–1 cells (1–2 copies) were used to check ampliﬁca-
tion sensitivity. Particular care was taken to prevent
contamination. Ampliﬁcations were carried out in a DNA thermal
cycler (Mastercycler, Eppendorf, Hamburg, Germany) and the
PCR products were analysed in 8% polyacrylamide gel. The pres-
ence of HPV DNA was researched by the combined use of two
HPV assays. Initially, the INNO-LiPA HPV Genotyping kit (Innoge-
netics N.V., Ghent, Belgium), based on the combined use of SPF10
PCR and LiPA hybridisation,30 was employed. The SPF general
primers detect at least 43 different HPV genotypes and the LiPA
type-speciﬁc assay identiﬁes 28 types. Due to the higher number
of HPV types detected by the SPF10 primers than the LiPA assay,
some samples yielded SPF10-positive/LiPA-negative results. These
HPV types were subsequently ampliﬁed by a highly sensitive
nested PCR assay, consisting of a ﬁrst step of ampliﬁcation with
the PGMY09/11 primer pair, followed by a second step with the
GP05+/GP06+ primers. The HPV genotyping procedure was based
on the direct sequencing of PGMY/GP-PCR fragments, utilising con-
sensus nested primers as sequencing primers. Brieﬂy, the ampliﬁ-
cation products were puriﬁed by Microcon1 YM-100 Filter Devices
(Amicon; Millipore, Billerica, MA), and approximately 5 ng of prod-
uct was added to 4 mL of BigDyeTM Terminator Ready Reaction
mix (Applied Biosystems, Foster City, CA). The puriﬁcation of reac-
tion mixtures and removal of free BigDyeTM was performed by
Centrisep Spin Columns (Princeton Separations, Adelphia, NJ) and
the mixture was analysed on an ABI PRISM1 310 Genetic Analyzer
(Applied Biosystems). Alignments were obtained from the online
BLAST server. HPV types were classiﬁed as Low Risk (LR) or HR
HPVs, according to a more recent classiﬁcation (online HPV Data-
base http://www.hpv-web.lanl.gov).31
Statistics
The data were analysed, using the SAS/STAT 8.0 package (SAS
Institute Inc., 100 SAS Campus Drive Cary, NC 27513-2414, USA).
The association between HPV infection detected by brushing and
biopsy, and demographical, behavioural and clinical-pathological
categorical variables was assessed using the v2 test or Fisher’s
exact test, as appropriate. The crude Odds Ratio (OR) with its
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60.05 was considered statistically signiﬁcant. Moreover, agree-
ment between two techniques was evaluated, using Cohen’s j
statistics with the following guidelines for index interpretation
(slightly adapted from Landis and Koch32): poor agreement; fair
agreement; moderate agreement; good agreement; and very good
agreement. As zero and all negative values of j indicate no agree-
ment, a one-tailed z test of the null hypothesis of no agreement
was also conducted.
Multivariate analysis (stepwise logistic regression model) was
used to assess the association between HPV infection detected by
each sampling method and OSCC, controlling for age, gender,
smoking and alcohol use, grading, site of lesion and degree of ker-
atinization. The adjusted OR with its respective 95% CI was also
calculated.Results
The study group included 40 females and 43 males, aged from
33 to 93 years (mean age: 64 years). The overall frequency of oral
HPV infection in the study population was 25.3% (21/83), indepen-
dent of the sampling procedures. Considering each method sepa-
rately, the frequency rate was higher with the brushing sampling
(13/83–15.7%) than with biopsy (10/83–12.1%), although devoid
of any statistical differences (p > 0.05). Table 1 shows the results
of HPV genotyping: with brushing, HPV types probably unrelated
to tumour were detected in four patients (three cases of infection
sustained by LR HPV 6 and one by the cutaneous type HPV 23);
all HPV-positive biopsies proved to be infected by HR types (more
frequent HPV 51, 16 and 39).
Both methods identiﬁed the same HPV status in 64/83 patients,
of which 62 were negative and, only in only two cases, did both
methods produce a type-speciﬁc concordant result (types
detected: HR HPV 35 and 39). Discordant HPV test results and
genotypes were observed in the remaining cases (eight cases with
HPV-positive biopsy and HPV-negative brushing; 11 cases withTable 1
Distribution of HPV types among HPV-positive OSCC patients by methods of
sampling.





















20 – 16, 56
21 – 51
In bold: concordant ﬁndings by both methods.
* Low risk HPV types.
§ Cutaneous HPV types.HPV-positive brushing and HPV-negative biopsy). Cohen’s j index
revealed poor agreement between the two techniques (j = 0.04,
p = 0.34).
Table 2 reports the results of a univariate analysis, performed
on demographical, behavioural and clinical-pathological variables.
HPV infection appeared more frequently in brushings of OSCC with
moderate grading G2 (p = 0.02; OR: 5.87), being associated with
alcohol abuse in biopsies (p = 0.001; OR: 13.21). However, these
associations were not conﬁrmed by the multivariate analysis
(Table 3).
Discussion
The aim of this cross-sectional study was to evaluate whether
the oral sampling method affects the assessment of HPV DNA fre-
quency in OSCC in a population of Sicilian patients. Unlike gynae-
cologists, who employ a standard sampling method for HPV testing
in the uterine cervix, a uniform method of specimen collection for
HPV detection in oral medicine still does not exist. Biopsy remains
one of the most common procedures of oral sampling, using the
same specimen for morphological examination as well as for the
HPV test, also in a different period of time. Moreover, biopsy pro-
vides a more representative sample of oral mucosa as compared
with exfoliative cytology, including cells from the basal layer,
where the virus could be present in a latent form.33 On the other
hand, exfoliative cytology is less invasive than a biopsy, it permits
the harvesting of cells from a greater surface area and involves a
lower risk of contamination prior to DNA extraction than a surgical
procedure.26,34,35
In order to reduce possible biases in this study due to the inclu-
sion of SCC originating from sites other than the oral cavity (strictly
deﬁned) and to minimise the use of the less efﬁcient virological
test, a classiﬁcation of tumour site, according to the AJCC criteria,
was deployed and a very sensitive method of HPV detection was
used for both specimens. The HPV DNA detection method applied
in this study is currently considered the gold standard for identiﬁ-
cation of all possible HPV types.16
The frequency of HPV DNA in OSCC in Sicilian patients observed
in this study was in line with data in the literature; indeed, the
overall prevalence of HPV (25.3%) fell within the range reported
from previous systematic reviews.20,23,24 Moreover, our ﬁndings
indicated that HPV infection was detected more frequently using
brushing than biopsy, although without any statistical signiﬁcance.
There are several studies conﬁrming the higher prevalence of HPV
DNA in cytological scrapes and mouthwashes than in tissue speci-
mens, either in normal oral mucosa26,36 or in OSCC.34,37 Herrero et
al., in a large multicentric study involving approximately 1500
OSCC patients, observed a prevalence of HPV DNA equal to 4.7%
in exfoliated cells and 3.9% in biopsy specimens. Of note, these re-
sults could be inﬂuenced by various factors linked to the varying
geographical origin of patients (Italy, Spain, Northern Ireland,
Poland, India, Cuba, Canada, Australia and Sudan and South Sudan)
and to exposure to other risk factors. Unfortunately, Herrero et al.
did not separately report the ﬁndings obtained from each geo-
graphical area, thus a speciﬁc comparison between frequency rates
obtained in Italy and our data was not feasible. A recent Italian
study38 reported a very low prevalence (1.6%) of HPV 16 infection
in 314 parafﬁn-embedded biopsies of OSCC. Nevertheless, the
authors of this research only investigated the 16, 18, 31 and 45
HPV types, rather than the overall HR HPV group. Thus, this meth-
odological discrepancy could be a possible explanation of the lower
prevalence of HPV than that found in this paper relating to OSCC
biopsies.
Further relevant outcomes emerging from the research in this
Paper were the enhanced ability of biopsy to detect HR types (as
Table 2




%HPV+ p OR (95% CI) nHPVþ
TOT
% HPV+ p OR (95% CI)
Age
666* 6/44 13.6 0.59 1.39 (0.42–4.59) 4/44 9.1 0.38 1.82 (0.47–7.09)
>66 7/39 18.0 6/39 15.4
Gender
Male* 6/40 15.0 0.87 1.10 (0.33–3.64) 5/40 12.5 0.90 0.92 (0.24–3.48)
Female 7/43 16.3 5/43 11.6
Smoke
No* 5/40 12.5 0.39 1.67 (0.51–5.44) 3/40 7 0.353 1.81 (0.51–6.41)
Yes 8/43 18.6 7/43 16.2
Alcohol
No* 9/67 13.4 0.27 2.37 (0.53–10.55) 6/67 8.9 0.001 13.21 (2.67–65.36)
Yes 4/16 25 4/16 25
Grading
G1§ 5/49 10.2 0.02 1.00 5/49 10.2 0.55 1.00
G2 6/15 40.0 5.87 (1.33–25.8) 2/15 13.3 1.36 (0.23–7.93)
G3 1/5 20.0 2.2 (0.20–24.5) 1/5 20.0 2.20 (0.20–24.5)
Site
Ventral tongue* 8/30 26.7 0.56 1.00 3/30 10.0 0.71 1.00
Dorsal tongue 0/6 0.0 – 1/6 16.7 1.8 (0.15–21.9)
Floor 1/6 16.7 0.55(0.05–5.69) 0/6 0.0 –
Gum 0/11 0.0 – 2/11 18.2 2.0 (0.28–14.5)
Cheek 1/11 9.1 0.28 (0.03–2.68) 3/11 27.3 3.38 (0.53–21.5)
Hard palate 1/5 20.0 0.69 (0.06–7.38) 0/5 0.0
Trigone 1/6 16.7 0.55 (0.05–5.69) 0/6 0.0
Multifocal 1/8 12.5 0.44 (0.04–7.58) 1/8 12.5 2.05 (0.18–28.7)
Site by keratinization
NK* 11/55 20 0.20 0.29 (0.03–1.53) 7/55 12.7 0.52 0.79 (0.12–3.85)
K 2/28 7.1 3/28 10.7
–, not calculated.
* Reference variable for OR assessment.
§ In 14 patients, G was not deﬁned by pathologist. In brushing group OR was calculated between the variables ‘‘G2 vs. G1’’; in biopsy group ORs were calculated for the
variables’’G2 vs. G1’’ and ‘‘G3 vs. G1’’, respectively.
Table 3
Multivariate analysis results in relation to demographical, behavioural and clinical-
pathological variables.
Variable Brushing Biopsy
OR0 95% CI OR0 95% CI
Age
>66 vs. 6 66 1.90 0.43–8.46 2.11 0.36–12.49
Gender
Female vs. Male 1.06 0.20–5.54 1.95 0.30–12.63
Smoke
Yes vs. No 1.35 0.24–7.69 1.1 0.13–9.51
Alcohol
Yes vs. No 3.77 0.64–22.30 5.93 0.87–40.35
Grading
G2 vs. G1 3.67 0.79–17.15 1.60 0.17–15.70
G3 vs. G1 3.80 0.23–61.68 1.88 0.12–29.80
Site*
Floor 0.39 0.03–4.91
Cheek 0.40 0.03–5.19 3.48 0.33–36.43
Multifocal 0.67 0.05–8.26 2.22 0.14–34.65
Site by keratinization
K vs. NK 0.67 0.05–8.26 1.70 0.17–17.11
* Some categories dropped because predict failure perfectly.
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two methods. These data suggest that the two sampling
procedures could have different features: brushing appears very
sensitive in detecting all HPV types in the oral cavity whereas
biopsy results are very accurate for detecting HR HPV in malignantlesions. In this context, the use of a cytobrush, less invasive and
easier to perform than a biopsy, may help to identify individuals
at risk of developing OSCC (e.g. patients with a genetic predisposi-
tion to acquiring HR HPV infection and/or those with a limited
immunological ability to eliminate the virus). More recently, an
oral rinse has been proposed as a more efﬁcient method of cytolog-
ical sampling than the superﬁcial brushing/scraping of oral mucosa
in terms of DNA yield, quality and stability. It is also acceptable to
the sample donor,27,36,39 even if further studies are required to con-
ﬁrm these preliminary data in order to optimise cytological sam-
pling methods in the strictly deﬁned oral cavity.
The lack of concordance between cytology and biopsy is not a
novel ﬁnding, having been previously reported.18,37,40 Herrero et
al. have reported the different results obtained between brushing
and biopsy in about 90% of cases, suggesting that the HPV status
of exfoliated oral cells probably does not accurately reﬂect that
of tumours; indeed, it could indicate a transient infection unrelated
to cancer development, or an HPV status arising after the occur-
rence of a tumour.
Syrjanen et al.18 have reported that the association of HPV with
OSCC was signiﬁcant only when HPV was detected in the biopsy
samples, the link being strongest when studies used biopsies for
HPV detection in both cases and controls. The signiﬁcant associa-
tion was completely lost when only exfoliated cells were used to
analyse HPV in both the cases and the controls, and this ﬁnding
has also been demonstrated in the genital tract.41 Considering that
HPV infection in the oral cavity and oropharynx is multifocal,
Syrjanen et al. have posited that exfoliative cytology could
produced more positive results due to the ease with which cells
can be collected from the suspect lesion. Thus, they concluded that,
874 N. Termine et al. / Oral Oncology 48 (2012) 870–875to obtain the most accurate results, only biopsied tissues should be
used for HPV testing.
With respect to the other variables investigated, no association
was found between HPV infection and any demographical and clin-
ical characteristic. And regarding association with common risk
factors, our results supported the hypothesis that HR HPV-positive
OSCC patients were more likely to be non-smokers than was the
case with uninfected cases, as previously described.9,11–13 Simi-
larly, data suggest that alcohol drinkers were more likely than
non-drinkers to have tumours with HPV DNA and this ﬁnding
has been described by other studies.27,42 Smith et al.27 have dem-
onstrated that alcohol abuse has an independent and synergistic
effect on HPV infection: the risk of HNSCC was increased (OR:
18.8) among heavy alcohol users who had been detected HPV-
positive than among drinker subjects who were HPV-negative. It
is biologically plausible that an interaction effect between HPV
and alcohol may occur: alcohol could biologically modify mucosal
tissue, potentially increasing its permeability to viral infection, or it
could inﬂuence the immune response to HPV.43 Nevertheless, the
association of alcohol with HPV infection was not conﬁrmed by
our multivariate analysis and by other studies,9,11,27,37,40,44–46
although it certainly merits further investigation.
Regarding pathological features and biological behaviour,
HPV-positive OSCCs probably form a distinct group with respect
to HPV-negative cases,46,47 and the identiﬁcation of this tumour
cluster would appear to be very important on the basis of the main
available parameters (i.e. histological grading and TNM stage
grouping). In a previous study,48 an association between HPV infec-
tion with TNM (stage II – T2), but not with a histological grading of
OSCC, was reported. Unfortunately, no data relating to TNM staging
were available from patients in this study, so this parameter was
not evaluated. This limitation was due to the fact that many pa-
tients, after a OSCC diagnosis, decided subjectively and autono-
mously to refer to other hospital for the stadiation of the tumour
and therapy (surgery and/or chemo-radiotherapy). As regards
grading, OSCC with moderate degrees of differentiation (G2) were
more likely to be HPV-positive (with brushing) than highly differ-
entiated tumours (G1), using both univariate and multivariate
analysis. The low number of undifferentiated tumours (G3) did
not permit us to verify the hypothesis of the likelihood of an in-
crease in HPV detection with a reducing histological differentiation
of tumours. A possible explanation could be that G2 tumours more
easily released cells from all epithelial layers than highly differen-
tiated OSCC. Of note, the association between G2 and HPV detec-
tion in OSCC was not conﬁrmed for biopsy sampling. The
relationship between the histological grading of HNSCCs and HPV
infection has been investigated in the literature, with controversial
ﬁndings. Various authors have observed a signiﬁcant frequency of
HPV infection among G3 tonsillar SCCs,49–51 and the same result
was obtained by Sugiyama for OSCC52; Higa et al.53 found an asso-
ciation of HPV infection with G1 OSCCs and Correnti et al.54 with
G2 oral cancers. However, other authors have failed to report any
association between HPV infection and grading score in both oral
and oropharyngeal SCC.55–59 We may speculate that these contra-
dictory results may be inﬂuenced by the small sample size, expo-
sure to other risk factors or by a genetic predisposition. More
simply, these contrasting results could reﬂect the scarce reproduc-
ibility and high subjectivity of grading assessment and, possibly,
the limited signiﬁcance of this parameter.
In conclusion, the results of this investigation conﬁrm that a
small fraction of OSCCs could be linked to HR HPV infection in
the Mediterranean area. Whilst devoid of statistical signiﬁcance,
the use of biopsy was demonstrated to be more accurate in detect-
ing HR HPV than superﬁcial brushing in the presence of a malig-
nant lesion, especially when highly sensitive procedures of viral
DNA identiﬁcation were used. Other studies, utilising differentmethods of investigation (case–control studies with several study
populations, the use of laser micro-dissection of tumour tissue,
other cytological sampling techniques, such as mouthwash) are
still required to validate the ﬁndings of this study in the Mediter-
ranean geographical area. And the optimisation and standardiza-
tion of the diagnostic procedure is a necessary requisite for
designing adequate preventive and therapeutic HPV targeting
strategies for future patients affected by oral and oropharyngeal
SCC.17Conﬂict of interest statement
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